Analytical Data
-
Gene name
CCL11
- Application
-
Alternative Names
C-C motif chemokine 11, Small-inducible cytokine A11
-
Species
Mouse
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 96% as determined by SDS-PAGE.
-
Uniprot
P48298
-
Expression Region
24-97aa
-
Protein Length
Partial
-
Molecular Weight
8.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL11, also known as Eotaxin-1, is a crucial chemokine involved in the allergic and inflammatory response, particularly in the recruitment of eosinophils. Elevated levels of CCL11 have been associated with various allergic diseases, such as asthma, rhinitis, and atopic dermatitis. The interest in CCL11 research stems from its potential role as a therapeutic target, as blocking its activity might alleviate eosinophilic inflammation and related symptoms. Recombinant CCL11 proteins have been developed to study their biological functions, signaling pathways, and receptor interactions in vitro and in vivo. These studies facilitate a better understanding of the chemokine’s involvement in immune responses and its implications in disease pathology. Moreover, recombinant CCL11 is being explored for use in preclinical models to evaluate potential anti-inflammatory therapies or targeted drug delivery systems. The characterization of this protein can also provide insights into its structure-function relationships and pave the way for new interventions in allergic and inflammatory disorders, making it a significant focus in immunological and therapeutic research.
